Brent Boyett, DMD
Family Medicine · Hamilton, ALNPI 1235211129
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 89.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $10,669 and has fallen 68.3% since, to $3,385 in 2025. Among family medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $204.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$29K
- Orexo US, Inc.$1K
- MDD US Operations, LLC$500
- Collegium Pharmaceutical, Inc.$364
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$226
- GRT US Holding, Inc.$211
- plus $712 from 18 others
Across 94 payments — averaging $3609.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$337K
- Kowa Research Institute, Inc.$2K
What the payments were for
- Consulting fees$11,67336%
- Speaking & faculty fees$13,56141%
- Travel & lodging$4,72014%
- Food & beverage$2,7849%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 79 | $29,329 |
| Orexo US, Inc. | 5 | $1,397 |
| MDD US Operations, LLC | 1 | $500 |
| Collegium Pharmaceutical, Inc. | 20 | $364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $226 |
| GRT US Holding, Inc. | 8 | $211 |
| Pear Therapeutics (US), Inc. | 3 | $122 |
| Averitas Pharma Inc. | 6 | $108 |
| Medtronic | 2 | $98 |
| Braeburn Inc. | 3 | $54 |
| Biodelivery Sciences International, Inc. | 4 | $52 |
| Alkermes, Inc. | 2 | $43 |
| Boston Scientific | 2 | $34 |
| Kaleo, Inc. | 2 | $31 |
| Krystal Biotech Inc | 1 | $25 |
| Gilead | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| AbbVie | 1 | $20 |
| Si-bone, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| SPR Therapeutics, Inc | 1 | $13 |
| Novartis | 1 | $12 |
| Corcept Therapeutics | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,740 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 139 | $124,388 |
| Buprenorphine | 296 | $86,073 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 387 | $39,285 |
| MovantikNaloxegol Oxalate | 62 | $25,416 |
| OxycontinOxycodone Hcl | 15 | $18,363 |
| LinzessLinaclotide | 23 | $12,073 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 585 | $11,089 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $6,455 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 197 | $6,044 |
| Xtampza ErOxycodone Myristate | 16 | $5,835 |
| Gabapentin | 317 | $3,329 |
| Naloxone Hcl | 47 | $3,307 |
| Pregabalin | 79 | $2,627 |
| Celecoxib | 50 | $2,162 |
| Morphine Sulfate ErMorphine Sulfate | 85 | $2,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $364 | $130,222155 claims |
| AbbVieLinzess | $20 | $12,07323 claims |
| Indivior Inc.Suboxone | $29,329 | $6,45512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Hamilton
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Philip WilsonDothan$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.